AstraZeneca (LON:AZN) Downgraded by Citigroup to “Buy”

AstraZeneca (LON:AZN) was downgraded by stock analysts at Citigroup to a “buy” rating in a research report issued on Friday,London Stock Exchange reports.

Several other equities research analysts also recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating and set a £115 price target on shares of AstraZeneca in a report on Friday, June 26th. Jefferies Financial Group reissued a “buy” rating and issued a £180 price target on shares of AstraZeneca in a research report on Friday, June 26th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of £153.33.

AstraZeneca Stock Down 1.6%

Shares of AZN opened at £131.34 on Friday. The stock has a market capitalization of £203.69 billion, a PE ratio of 19.78, a P/E/G ratio of 0.86 and a beta of 0.23. AstraZeneca has a 1 year low of £101.78 and a 1 year high of £157.32. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91. The company’s 50-day simple moving average is £137.31 and its 200-day simple moving average is £141.54.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.